Upcoming phase II study to discover personalized therapy for patients at high risk for breast cancer relapse

Upcoming phase II study to discover personalized therapy for patients at high risk for breast cancer relapse

Upcoming phase II study to discover personalized therapy for patients at high risk for breast cancer relapse

Indiana University School of Medicine researchers Milan Radovich, PhD, and Bryan Schneider, MD, have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women's blood who have undergone chemotherapy prior to surgery for the treatment of stage 1, 2 or 3 triple negative breast cancer are critical indicators for the prediction of disease recurrence and disease-free survival.